Adverum Biotechnologies, Inc.
ADVMDelisted Dec 9, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501756
Adverum Biotechnologies, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 10, 2025; 50 institutions reported holding it in 13F filings for Q3 2025, worth $63.8M in total; no superinvestor held it.
Holders of 5% or more of ADVM
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Adverum Biotechnologies, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 13G/A | 8.90%1.87M shares | – | Feb 15, 20242 filings | May 15, 2025 | SEC |
| Rush Ryan Bradford | 13G | 5.10%1.05M shares | New | Dec 17, 20241 filing | Dec 17, 2024 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
68 Schedule 13D and 13G filings on Adverum Biotechnologies, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Apr 11, 2022 | FMR LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 20224:07 PM ET | Regeneron Pharmaceuticals, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | OrbiMed Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 3, 20224:41 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Oct 12, 2021 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Sep 10, 2021 | State Street Corp | 13GOld format | – | New | – | SEC |
| Aug 16, 2021 | Ra Capital Management, L.P. | 13GOld format | – | – | – | SEC |
| Apr 16, 2021 | Sonic Fund II, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 9, 2021 | Sonic Fund II, L.P. | 13D/AOld format | – | – | – | SEC |
| Mar 18, 2021 | Sonic Fund II, L.P. | 13DOld format | – | – | – | SEC |
| Feb 16, 2021 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Sonic Fund II, L.P. | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | OrbiMed Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Jan 28, 20215:56 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Adverum Biotechnologies, Inc. shares.
No Form 144 notices for Adverum Biotechnologies, Inc. are on file.